591 related articles for article (PubMed ID: 18940269)
1. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies.
Iberer F; Halwachs-Baumann G; Rödl S; Pleisnitzer A; Wasler A; Auer T; Petutschnigg B; Müller H; Tscheliessnigg K; Wilders-Truschnig M
J Heart Lung Transplant; 1994; 13(3):405-11. PubMed ID: 8061015
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
4. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation.
Sarmiento E; Rodríguez-Molina J; Muñoz P; Fernández-Yánez J; Palomo J; Fogueda M; Fernández-Cruz E; Bouza E; Carbone J
Transplant Proc; 2005 Nov; 37(9):4046-9. PubMed ID: 16386623
[TBL] [Abstract][Full Text] [Related]
5. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
6. Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel AA; Yefenof E
Bone Marrow Transplant; 1996 Feb; 17(2):237-41. PubMed ID: 8640173
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
8. IgG monitoring to identify the risk for development of infection in heart transplant recipients.
Sarmiento E; Rodriguez-Molina JJ; Fernandez-Yañez J; Palomo J; Urrea R; Muñoz P; Bouza E; Fernandez-Cruz E; Carbone J
Transpl Infect Dis; 2006 Mar; 8(1):49-53. PubMed ID: 16623821
[TBL] [Abstract][Full Text] [Related]
9. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
[TBL] [Abstract][Full Text] [Related]
10. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection.
Eid AJ; Brown RA; Arthurs SK; Lahr BD; Eckel-Passow JE; Larson TS; Razonable RR
Transpl Int; 2010 May; 23(5):506-13. PubMed ID: 19951371
[TBL] [Abstract][Full Text] [Related]
11. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.
Carbone J; Sarmiento E; Palomo J; Fernandez-Yañez J; Muñoz P; Bouza E; Rodríguez-Molina J; Lanio N; Fernandez-Cruz E
Transplant Proc; 2007 Sep; 39(7):2385-8. PubMed ID: 17889198
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
[TBL] [Abstract][Full Text] [Related]
13. Gancyclovir prophylaxis in high risk patients.
Campino A
Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
15. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
Potena L; Holweg CT; Chin C; Luikart H; Weisshaar D; Narasimhan B; Fearon WF; Lewis DB; Cooke JP; Mocarski ES; Valantine HA
Transplantation; 2006 Aug; 82(3):398-405. PubMed ID: 16906040
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
[TBL] [Abstract][Full Text] [Related]
20. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
